Aclerastide, an analog of angiotensin 1-7, shows strong potential in treating diabetic foot ulcers through progenitor proliferation, vascularization, collagen deposition, and re-epithelialization. Preclinical studies demonstrate its superiority over existing topical growth factors, with Phase II…
Aclerastide acts as an angiotensin receptor agonist and serves as the key component in a topical formulation. This compound mimics the natural peptide angiotensin 1-7. It promotes healing by stimulating progenitor cell growth, speeding up blood vessel formation, boosting collagen buildup, and aiding skin regrowth.
Standard care focuses on keeping wounds moist, using proper bandages, reducing pressure through offloading, and managing infections via debridement. One approved topical growth factor exists but requires strict monitoring. New options like aclerastide offer a fresh approach without relying on growth factors.
Diabetes slows natural repair, leading to persistent infected wounds. Current methods often fall short against this burden.
Animal studies reveal aclerastide outperforms the topical growth factor in closing diabetic wounds. Wounds first fill with extracellular matrix resembling healthy skin, followed by skin regrowth that appears nearly scar-free under the microscope.
This process translates to humans, as seen in wound volume shrinking first, then area reduction, and full closure. Check the Peptide Glossary /tools/peptide-glossary for details on peptide analogs like angiotensin 1-7.
Aclerastide works via the Mas receptor, part of the protective branch of the renin-angiotensin system. Blocking this receptor with A779 halts its healing effects. It reduces inflammation and restores normal tissue repair processes Rodgers et al. 2015 . NorLeu3-A 1-7 represents the structure of aclerastide.
These actions explain the quality of repair in diabetic mouse models. Inflammation drops, allowing balanced healing.
Phase I trials in diabetic foot ulcer patients confirmed good tolerability and no drug detected in the bloodstream. Phase II results showed faster wound closure after 4 weeks of treatment, with more wounds fully closed and staying that way for up to 20 weeks.
Pivotal Phase III trials are recruiting participants now. Development continues as a topical agent for these ulcers Notte, T. N. 2014 .
Use tools like the Dosage & Cycle Planner /tools/peptide-dosage-planner or Stability Calculator /tools/peptide-storage-guide for research on similar compounds.
Studies cover skin irritation, long-term skin exposure in miniswine, whole-body effects in dogs and rats, and reproduction impacts. All support safe extended use in patients. Carcinogenicity tests remain in progress.
Pharmacology confirms its profile for diabetic foot ulcer therapy Rodgers et al. 2015 .
Aclerastide advances diabetic foot ulcer treatment with proven preclinical and early clinical benefits. Its unique mechanism via the Mas receptor sets it apart. Ongoing Phase III trials will clarify its full potential. Explore our catalog /catalog for related research compounds.
Peptides referenced: Angiotensin 1-7.
Related reading: Aviptadil Acetate's Potential in Pulmonary Arterial Hypertension, Atosiban Serves as Maintenance Therapy for Preterm Labor, Peptide Atlas Terms of Service for Research Purchases, TB4 Peptide: Key Functions and Research Insights.